<< Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009 | Conference to discuss cost savings and payback of personal companion robots >>
Read in | English | Español | 日本語 | 简体中文 | Русский

Report on opportunities in the global H1N1 2009 influenza vaccine market

Published on October 22, 2009 at 7:07 AM · No Comments

A new market research report, 'Global H1N1 2009 Influenza Vaccine', published by MarketsandMarkets (http://www.marketsandmarkets.com) analyzes the global H1N1 2009 Influenza vaccine market over the period 2009-2012. The report studies the major market drivers, restraints, and opportunities for global H1N1 2009 Influenza vaccine market and also evaluates the major pandemic trends with respect to different geographic regions.

Browse in-depth TOC on stem cell market. Early buyers will receive 10% customization of report.

http://www.marketsandmarkets.com/Market-Reports/influenza-vaccines-market-159.html

The global H1N1 2009 Influenza vaccine market is estimated to be $7,028 billion by 2011, growing at a CAGR of 222.4 % from 2009 to 2011. Some of the key players in this market are GlaxoSmithKline, Novartis, CSL, MedImmune, Sanofi-Pasteur, Solvay, Sinovac Biotech and Hualun Biologicals.

The global H1N1 2009 Influenza vaccine market is growing due to the prevailing pandemic of H1N1 influenza and huge demand from different countries for the vaccines against it. The H1N1 Influenza vaccine market is mainly driven by the increasing awareness of the population, global spread of H1N1 influenza and the initiatives taken by government & other public institutions for immunization of the population against H1N1 influenza. The North America region is the current lucrative market for H1N1 influenza vaccines with other regions also having high infection rate across the population.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading